Tempus AI Launches Next-Gen Lens Platform to Accelerate Oncology Drug Development

--- headline: "Tempus AI Launches Next-Gen Lens Platform to Accelerate Oncology Drug Development" slug: tempus-lens-agentic-oncology-drug-dev category: research story_number: "11" date: 2026-06-04 author: The Vault AI Edition ---

# Tempus AI Launches Next-Gen Lens Platform to Accelerate Oncology Drug Development

The Chicago-based precision medicine company unveils an agentic AI system backed by 8.5 million patient records and already adopted by 19 of the top 20 biopharma firms, positioning Lens as a co-scientist for clinical trial design and biomarker validation.

CHICAGO -- Tempus AI (NASDAQ: TEM) has rolled out the next generation of Lens, its agentic AI platform purpose-built to compress the timeline and cost of oncology drug development. Announced on May 31, the upgraded platform stitches together more than a decade of longitudinal real-world clinical data, high-performance AI compute, proprietary oncology foundation models, and a suite of validated autonomous agents into a single workflow -- one that the company says can turn months of manual biostatistical analysis into minutes of machine-driven execution.

The stakes are enormous. Drug development remains one of the most expensive and failure-prone endeavors in the global economy, with average costs to bring a single oncology compound from molecule to market often exceeding $2 billion and timelines stretching beyond a decade. Tempus is betting that agentic AI -- software agents capable of planning, executing, and iterating on complex analytical tasks with minimal human oversight -- can fundamentally reshape that calculus.

How Lens Works

At the core of the upgraded platform is Tempus One, a co-scientist agent that allows drug development teams to pose complex biological hypotheses in plain language and receive a targeted, executable analysis plan in return. Rather than requiring weeks of back-and-forth between data scientists and clinical researchers, the agent draws on deep contextual knowledge of the Tempus real-world data model and the specific datasets available within a project to propose an analytical path that users can refine through direct collaboration.

Once a research plan is finalized, the agent executes the analysis in code against the company’s multimodal data library -- which now encompasses more than 8.5 million queryable de-identified patient records spanning genomic sequencing, clinical notes, imaging, lab results, and treatment outcomes. Results are delivered in minutes via interactive, shareable reports. For full transparency, researchers can toggle into a “code view” to audit the underlying analytical logic or export the entire project to a private workspace for further technical extension.

The platform also deploys specialized AI agents custom-validated for specific phases of drug development. Biomarker validation agents help teams confirm whether a candidate biomarker reliably predicts treatment response across real-world patient populations. Trial design support agents assist in identifying optimal patient subgroups, refining inclusion and exclusion criteria, and projecting enrollment feasibility -- decisions that can shave months off a clinical program if made correctly, or sink it entirely if botched.

“Drug development requires thousands of pivotal decisions between molecule and approval, and at its core, it is a navigation problem -- most paths end in dead studies and wasted capital, which is why the industry needs a fundamentally different approach,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “The next generation of Lens consolidates this workflow into a single platform, with Tempus One serving as a co-scientist that does much of the heavy lifting. We’ve tuned every layer of the platform to empower biopharma teams to see the optimal development path clearly and make critical decisions faster than ever before.”

Scale and Traction

Tempus says Lens is commercially available today at lens.tempus.ai and is already used by 19 of the top 20 largest biopharma companies -- a penetration rate that speaks to the platform’s positioning as infrastructure rather than experiment. The company’s broader financial trajectory supports the narrative: in Q1 2026, Tempus reported 36 percent year-over-year revenue growth, with diagnostics bringing in $261.1 million and data and services contributing $87 million. The company ended March with $643.8 million in cash and raised its full-year 2026 adjusted EBITDA guidance to approximately $65 million.

The Gilead Sciences partnership, expanded in April 2026, offers a concrete illustration of how the platform is being deployed at scale. Where Gilead previously accessed Tempus capabilities on a program-by-program basis, the expanded multi-year agreement now provides enterprise-wide access to the Lens platform across multiple oncology indications, integrating dedicated Tempus analytical services for trial design, indication selection, biomarker strategy, and health outcomes analysis.

CEO Eric Lefkofsky has framed the company’s broader vision as an “AI flywheel”: “Every insight strengthens our models, and every model helps generate more clinically meaningful insights for providers and patients. This is our AI flywheel in action: transforming complex information into timely insights, delivered to physicians when they need them most.”

The Bigger Picture

Tempus is entering a competitive but fast-growing market. Flatiron Health, owned by Roche, has long been a leading provider of oncology real-world evidence. Veracyte, Foundation Medicine, and a growing roster of AI-native startups are all vying for pieces of the biopharma data and analytics market. What distinguishes the Lens upgrade is the agentic architecture -- the move from passive data access to active, agent-driven analysis that can plan, execute, and explain its own work.

The announcement also arrives at a moment when the broader biopharma industry is under intense pressure to cut development timelines. According to industry analyses, the average Phase III oncology trial takes more than four years to complete, and roughly 95 percent of oncology drug candidates that enter clinical testing ultimately fail. If Lens can meaningfully accelerate the identification of viable biomarkers and improve trial design, even marginal improvements in success rates could translate to billions of dollars in recovered R&D investment across the industry.

For now, the clearest signal of Lens’s impact is its adoption curve. When 19 of the 20 largest biopharma companies are already on the platform, the question is no longer whether agentic AI has a role in drug development -- it is how deeply it will reshape the process.